Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.

Novak, Alison R; Shakowski, Courtney; Trujillo, Toby C; Wright, Garth C; Mueller, Scott W; Kiser, Tyree H

Novak, Alison R; Shakowski, Courtney; Trujillo, Toby C; Wright, Garth C; Mueller, Scott W; Kiser, Tyree H.

Affiliation

Novak AR; Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E Montview Blvd, C238, Aurora, CO, 80045, USA.
Shakowski C; Department of Pharmacy, University of Colorado Hospital, UCHealth, Aurora, CO, USA.
Trujillo TC; Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E Montview Blvd, C238, Aurora, CO, 80045, USA.
Wright GC; Department of Pharmacy, University of Colorado Hospital, UCHealth, Aurora, CO, USA.
Mueller SW; Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E Montview Blvd, C238, Aurora, CO, 80045, USA.
Kiser TH; Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E Montview Blvd, C238, Aurora, CO, 80045, USA.

J Thromb Thrombolysis ; 54(2): 276-286, 2022 Aug.

Article in En | MEDLINE | ID: mdl-35689140

Subject(s)

Atrial Fibrillation; Obesity, Morbid; Stroke; Venous Thromboembolism; Administration, Oral; Anticoagulants/adverse effects; Atrial Fibrillation/drug therapy; Hemorrhage/chemically induced; Hemorrhage/drug therapy; Humans; Retrospective Studies; Rivaroxaban/therapeutic use; Stroke/drug therapy; Thinness/chemically induced; Thinness/drug therapy; Venous Thromboembolism/chemically induced; Venous Thromboembolism/drug therapy; Warfarin/adverse effects

Key words

Apixaban; BMI; DOAC; Dabigatran; Edoxaban; Extreme body weight; Obese; Recurrent thromboembolism; Rivaroxaban; Severe bleeding; Underweight; Warfarin

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Obesity, Morbid / Stroke / Venous Thromboembolism Type of study: Observational_studies Limits: Humans Language: En Journal: J Thromb Thrombolysis Journal subject: ANGIOLOGIA Year: 2022 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google